Skip to main content
. 2023 Feb 14;30(2):2277–2289. doi: 10.3390/curroncol30020176

Figure 2.

Figure 2

Kaplan–Meier curves of OS (unadjusted) after first-line or second-line treatment in EC patients treated with or without PBCT. (A) OS from first-line therapy in patients with recurrent (orange) or advanced (blue) EC. The corresponding table shows the number at risk at each time point (log-rank p = 0.6). (B) OS from second-line therapy among patients treated with first-line platinum-based chemotherapy with recurrent (orange) or advanced (blue) EC; p = 0.5 (C) OS from second-line therapy among patients who received a platinum regimen in the first line and were then rechallenged with platinum-based chemotherapy (blue) vs. those with no rechallenge (orange). Dotted lines indicate median survival at a 50% survival probability; p < 0.001. OS, overall survival.